Quick answers
- What is Piperacillin and tazobactam used for?
- The FDA-approved label (Zosyn in Galaxy Containers, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., March 15, 2023) says: “ZOSYN is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older • Skin and skin structure infections in adults • Female pelvic infections in adults • …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Piperacillin and tazobactam have a boxed warning?
- The label we quote has no boxed warning, but 5 of 33 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Piperacillin and tazobactam?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated January 20, 2026). Ask your pharmacist about alternatives.
- Has Piperacillin and tazobactam been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started July 2, 2018 (Class I). A recall usually concerns specific lots, not every product.
- Who makes Piperacillin and tazobactam?
- 18 companies list prescription products of Piperacillin and tazobactam in the FDA NDC Directory, including Fresenius Kabi USA, LLC, Eugia US LLC and Provepharm Inc..
What Piperacillin and tazobactam is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ZOSYN is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older • Skin and skin structure infections in adults • Female pelvic infections in adults • …
— FDA label: Zosyn in Galaxy Containers, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective March 15, 2023. Read the full label on DailyMed →
The FDA has 33 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
5 of 33 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, for solution · Injection, powder, lyophilized, for solution · Injection, solution |
|---|---|
| Route | Intravenous · Parenteral |
| Prescription products | 70 in the FDA NDC Directory |
| Brand names | Zosyn in Galaxy Containers, Zosyn |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| piperacillin sodium 3 g · tazobactam sodium 0.375 g injection, powder, for solution | Generic | $3.49 per unit |
| piperacillin sodium 3 g · tazobactam sodium 0.375 g injection, powder, lyophilized, for solution | Generic | $3.49 per unit |
| piperacillin sodium 3 g/15 mL · tazobactam sodium 0.375 g/15 mL injection, powder, for solution | Generic | $3.49 per unit |
| piperacillin sodium 3 g/15 mL · tazobactam sodium 0.375 g/15 mL injection, powder, lyophilized, for solution | Generic | $3.49 per unit |
NADAC list of November 4, 2026; these prices took effect on January 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Fresenius Kabi USA, LLC22 products
- Eugia US LLC8 products
- Provepharm Inc.5 products
- Sandoz Inc5 products
- Civica, Inc.4 products
- Apotex Corp.4 products
- Avenacy, LLC4 products
- WG Critical Care, LLC4 products
- Shandong Anxin Pharmaceutical Co., Ltd.4 products
- Hospira, Inc.4 products
- Onesource Specialty Pharma Limited3 products
- BluePoint Laboratories3 products
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.3 products
- B. Braun Medical Inc.3 products
- Baxter Healthcare Corporation3 products
- Milla Pharmaceuticals Inc.2 products
- Armas Pharmaceuticals Inc.2 products
- Sagent Pharmaceuticals1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA050750 ZOSYN IN PLASTIC CONTAINER | Baxter Hlthcare Corp | February 24, 1998 | 37, latest December 3, 2024 2024: Labeling · 2024: Labeling · 2024: Labeling |
| NDA206056 PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | B Braun Medical | April 3, 2025 | — |
Generic approvals (14)
- ANDA065362Sandoz · October 21, 2010
- ANDA065498Eugia Pharma Speclts · May 23, 2011
- ANDA065523Acs Dobfar Spa · May 31, 2011
- ANDA090498Acs Dobfar Spa · May 31, 2011
- ANDA065458Onesource Specialty · August 15, 2014
- ANDA203557Sandoz · October 29, 2014
- ANDA207847Milla Pharms · January 13, 2017
- ANDA207848Milla Pharms · January 13, 2017
- ANDA203720Fresenius Kabi · May 11, 2018
- ANDA203719Fresenius Kabi · May 18, 2018
- ANDA204959Shandong · August 10, 2018
- ANDA208675Sagent Pharms Inc · February 16, 2021
- ANDA217243Shandong · April 14, 2023
- ANDA217409Eugia Pharma · October 12, 2023
Shortage status
To be discontinued · updated January 20, 2026 · first posted January 20, 2026
| Product | Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20) |
|---|---|
| Company | Fresenius Kabi USA, LLC |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 2, 2018 · Class I · Terminated · D-1030-2018
Presence of Particulate Matter: identified as glass and silicone material
Piperacillin and Tazobactam for Injection USP 3.375 grams per vial, Single-Dose Vial, Rx Only. Manufactured for: Auromedics Pharma LLC 6 Wheeling Road Dayton NJ 08810, Made in India. NDC 55150-120-30 — AuroMedics Pharma LLC
-
May 1, 2018 · Class I · Terminated · D-0926-2018
Presence of Particulate Matter: confirmed customer report for presence of visible particulate matter, confirmed as glass
Piperacillin and Tazobactam for Injection, USP 3.375 grams per vial, For Intravenous Use Only, Single-Dose vial, Rx Only, Manufactured for: AuroMedics Pharma LLC, 6 Wheeling Road, Dayton, NJ 05610. NDC 55150-120-30 — AuroMedics Pharma LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Zosyn in Galaxy Containers, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective March 15, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →